vs
豪洛捷（HOLX）与西方石油（OXY）财务数据对比。点击上方公司名可切换其他公司
西方石油的季度营收约是豪洛捷的1.6倍（$1.7B vs $1.0B），豪洛捷净利率更高（17.1% vs 6.9%，领先10.2%），豪洛捷同比增速更快（2.5% vs -75.8%），西方石油自由现金流更多（$1.9B vs $215.2M），过去两年豪洛捷的营收复合增速更高（1.5% vs -50.4%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
西方石油是一家美国能源企业，核心业务覆盖美国及中东地区的油气勘探，以及美国、加拿大、智利的石化产品制造。公司注册于特拉华州，总部位于休斯顿，2021年分别位列财富500强第183位、福布斯全球企业2000强第670位。
HOLX vs OXY — 直观对比
营收规模更大
OXY
是对方的1.6倍
$1.0B
营收增速更快
HOLX
高出78.4%
-75.8%
净利率更高
HOLX
高出10.2%
6.9%
自由现金流更多
OXY
多$1.7B
$215.2M
两年增速更快
HOLX
近两年复合增速
-50.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.7B |
| 净利润 | $179.1M | $114.0M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | -6.5% |
| 净利率 | 17.1% | 6.9% |
| 营收同比 | 2.5% | -75.8% |
| 净利润同比 | -10.9% | 195.0% |
| 每股收益（稀释后） | $0.79 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXOXY
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $6.7B | ||
| Q2 25 | $1.0B | $6.3B | ||
| Q1 25 | $1.0B | $6.9B | ||
| Q4 24 | $1.0B | $6.9B | ||
| Q3 24 | $988.0M | $7.0B | ||
| Q2 24 | $1.0B | $6.8B | ||
| Q1 24 | $1.0B | $6.7B |
净利润HOLXOXY
| Q4 25 | $179.1M | $114.0M | ||
| Q3 25 | $187.2M | $842.0M | ||
| Q2 25 | $194.9M | $468.0M | ||
| Q1 25 | $-17.4M | $945.0M | ||
| Q4 24 | $201.0M | $-120.0M | ||
| Q3 24 | $178.6M | $1.1B | ||
| Q2 24 | $194.5M | $1.2B | ||
| Q1 24 | $169.9M | $888.0M |
毛利率HOLXOXY
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | 87.8% | ||
| Q2 25 | 56.3% | 86.6% | ||
| Q1 25 | 37.5% | 88.4% | ||
| Q4 24 | 56.8% | 89.0% | ||
| Q3 24 | 56.4% | 88.5% | ||
| Q2 24 | 55.4% | 87.9% | ||
| Q1 24 | 53.3% | 89.0% |
营业利润率HOLXOXY
| Q4 25 | 22.6% | -6.5% | ||
| Q3 25 | 22.6% | 17.4% | ||
| Q2 25 | 24.9% | 11.7% | ||
| Q1 25 | -0.7% | 19.3% | ||
| Q4 24 | 22.5% | -2.5% | ||
| Q3 24 | 23.3% | 22.7% | ||
| Q2 24 | 24.1% | 24.0% | ||
| Q1 24 | 20.7% | 15.0% |
净利率HOLXOXY
| Q4 25 | 17.1% | 6.9% | ||
| Q3 25 | 17.8% | 12.6% | ||
| Q2 25 | 19.0% | 7.4% | ||
| Q1 25 | -1.7% | 13.7% | ||
| Q4 24 | 19.7% | -1.7% | ||
| Q3 24 | 18.1% | 16.2% | ||
| Q2 24 | 19.2% | 17.2% | ||
| Q1 24 | 16.7% | 13.2% |
每股收益（稀释后）HOLXOXY
| Q4 25 | $0.79 | $-0.07 | ||
| Q3 25 | $0.84 | $0.65 | ||
| Q2 25 | $0.86 | $0.26 | ||
| Q1 25 | $-0.08 | $0.77 | ||
| Q4 24 | $0.87 | $-0.32 | ||
| Q3 24 | $0.75 | $0.98 | ||
| Q2 24 | $0.82 | $1.03 | ||
| Q1 24 | $0.72 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $2.0B |
| 总债务越低越好 | $2.5B | $20.6B |
| 股东权益账面价值 | $5.2B | $36.0B |
| 总资产 | $9.2B | $84.2B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资HOLXOXY
| Q4 25 | $2.4B | $2.0B | ||
| Q3 25 | $2.2B | $2.2B | ||
| Q2 25 | $1.9B | $2.3B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $2.0B | $2.1B | ||
| Q3 24 | $2.3B | $1.8B | ||
| Q2 24 | $2.4B | $1.8B | ||
| Q1 24 | $2.2B | $1.3B |
总债务HOLXOXY
| Q4 25 | $2.5B | $20.6B | ||
| Q3 25 | $2.5B | $20.8B | ||
| Q2 25 | $2.5B | $23.3B | ||
| Q1 25 | $2.5B | $24.0B | ||
| Q4 24 | $2.5B | $25.0B | ||
| Q3 24 | $2.5B | $25.5B | ||
| Q2 24 | $2.5B | $18.4B | ||
| Q1 24 | $2.6B | $18.5B |
股东权益HOLXOXY
| Q4 25 | $5.2B | $36.0B | ||
| Q3 25 | $5.0B | $36.3B | ||
| Q2 25 | $4.8B | $35.7B | ||
| Q1 25 | $4.6B | $34.7B | ||
| Q4 24 | $4.8B | $34.2B | ||
| Q3 24 | $5.1B | $34.7B | ||
| Q2 24 | $5.0B | $32.1B | ||
| Q1 24 | $4.8B | $30.8B |
总资产HOLXOXY
| Q4 25 | $9.2B | $84.2B | ||
| Q3 25 | $9.0B | $83.5B | ||
| Q2 25 | $8.8B | $84.4B | ||
| Q1 25 | $8.5B | $85.0B | ||
| Q4 24 | $8.7B | $85.4B | ||
| Q3 24 | $9.2B | $85.8B | ||
| Q2 24 | $8.9B | $76.2B | ||
| Q1 24 | $8.7B | $74.3B |
负债/权益比HOLXOXY
| Q4 25 | 0.48× | 0.57× | ||
| Q3 25 | 0.50× | 0.57× | ||
| Q2 25 | 0.52× | 0.65× | ||
| Q1 25 | 0.55× | 0.69× | ||
| Q4 24 | 0.53× | 0.73× | ||
| Q3 24 | 0.49× | 0.73× | ||
| Q2 24 | 0.51× | 0.57× | ||
| Q1 24 | 0.53× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $2.6B |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $1.9B |
| 自由现金流率自由现金流/营收 | 20.5% | 113.4% |
| 资本支出强度资本支出/营收 | 1.4% | 45.4% |
| 现金转化率经营现金流/净利润 | 1.28× | 23.11× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $4.1B |
8季度趋势，按日历期对齐
经营现金流HOLXOXY
| Q4 25 | $229.9M | $2.6B | ||
| Q3 25 | $355.1M | $2.8B | ||
| Q2 25 | $343.3M | $3.0B | ||
| Q1 25 | $169.4M | $2.1B | ||
| Q4 24 | $189.3M | $3.4B | ||
| Q3 24 | $367.0M | $3.7B | ||
| Q2 24 | $405.8M | $2.4B | ||
| Q1 24 | $292.4M | $2.0B |
自由现金流HOLXOXY
| Q4 25 | $215.2M | $1.9B | ||
| Q3 25 | $341.4M | $1.0B | ||
| Q2 25 | $330.5M | $962.0M | ||
| Q1 25 | $153.9M | $240.0M | ||
| Q4 24 | $172.5M | $1.6B | ||
| Q3 24 | $350.6M | $2.0B | ||
| Q2 24 | $385.3M | $623.0M | ||
| Q1 24 | $279.6M | $224.0M |
自由现金流率HOLXOXY
| Q4 25 | 20.5% | 113.4% | ||
| Q3 25 | 32.5% | 15.3% | ||
| Q2 25 | 32.3% | 15.2% | ||
| Q1 25 | 15.3% | 3.5% | ||
| Q4 24 | 16.9% | 23.0% | ||
| Q3 24 | 35.5% | 28.5% | ||
| Q2 24 | 38.1% | 9.2% | ||
| Q1 24 | 27.5% | 3.3% |
资本支出强度HOLXOXY
| Q4 25 | 1.4% | 45.4% | ||
| Q3 25 | 1.3% | 26.5% | ||
| Q2 25 | 1.3% | 31.6% | ||
| Q1 25 | 1.5% | 27.6% | ||
| Q4 24 | 1.6% | 26.0% | ||
| Q3 24 | 1.7% | 24.0% | ||
| Q2 24 | 2.0% | 26.0% | ||
| Q1 24 | 1.3% | 26.5% |
现金转化率HOLXOXY
| Q4 25 | 1.28× | 23.11× | ||
| Q3 25 | 1.90× | 3.31× | ||
| Q2 25 | 1.76× | 6.32× | ||
| Q1 25 | — | 2.27× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 3.23× | ||
| Q2 24 | 2.09× | 2.05× | ||
| Q1 24 | 1.72× | 2.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
OXY
暂无分部数据
